INMBINmune Bio, Inc.

$35M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$155,000-58.6% YoY

Gross Profit

$155,000100.0% margin

Operating Income

-$30M-19187.7% margin

Net Income

-$30M-19360.0% margin

EPS (Diluted)

$-1.67

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$57M

Total Liabilities

$19M

Stockholders' Equity

$38M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$155,000	$374,000	-58.6%
Gross Profit	$155,000	$374,000	-58.6%
Operating Income	-$30M	-$26M	-14.6%
Net Income	-$30M	-$27M	-9.9%

INMB FY 2023 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena